ASH 2022 | Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, shares the key topics discussed at a session on resistance to immunotherapy in plasma cell dyscrasias that took place at ASH, including the mechanisms of resistance to daratumumab and CELMoDs, and the increasing use of single-cell techniques to monitor resistance. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.
